secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001558370-25-002093
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports FY2024 net loss $64.8M, cash $76.8M; PBFT02 shows durable PGRN elevation in FTD-GRN
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $76.8M as of Dec 31, 2024, down from $114.3M; runway extended into 1Q 2027.
- Net loss of $12.7M ($0.20 per share) for Q4 2024 vs $16.8M ($0.30) a year ago; full year net loss $64.8M ($1.07) vs $102.1M.
- Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to 13-27 ng/mL at 6 months (n=4) and 22-34 ng/mL at 12 months (n=2).
- Plasma NfL levels 13% lower vs baseline at 12 months vs expected 29% annual increase from natural history data.
- First FTD-GRN patient enrolled with Dose 2 (50% lower); plan to report 12-month data and interim Dose 2 data in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837025002093/0001558370-25-002093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837025002093/pasg-20250304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer